References
- Bertuccio P, Chatenoud L, Levi F, et al (2009). Recent patterns in gastric cancer: a global overview. Int J Cancer, 125, 666-73. https://doi.org/10.1002/ijc.24290
- Cox DR (1972). Regression models and life-tables. J R Stat Soc B, 34, 187-220.
- Dikshit RP, Mathur G, Mhatre S, et al (2011). Epidemiological review of gastric cancer in India. Indian J Med Paediatr Oncol, 32, 3. https://doi.org/10.4103/0971-5851.81883
- Herberman RB (1977). Immunologic tests in diagnosis of cancer. Am J Clin Pathol, 68, 688-98.
- Ishigami S, Natsugoe S, Hokita S, et al (2001). Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol, 32, 41-4. https://doi.org/10.1097/00004836-200101000-00010
- Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81. https://doi.org/10.1080/01621459.1958.10501452
- Jager KJ, van Dijk PC, Zoccali C, et al (2008). The analysis of survival data: the kaplan-meier method. Kidney Int, 74, 560-5. https://doi.org/10.1038/ki.2008.217
- Kato K, Taniguchi M, Kawakami T, et al (2011). Gastric Cancer with a Very High Serum CA 19-9 Level. Case Rep Gastroenterol, 5, 258-61. https://doi.org/10.1159/000327984
- Kodera Y, Yamamura Y, Torii A, et al (1996). The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol, 91, 49-53.
- Kokociñska D, Jarzab B, Król R, et al (1996). A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers. J Environ Pathol Toxicol Oncol, 15, 283-7.
- Kono K, Amemiya H, Sekikawa T (2002).Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg, 19, 359-65. https://doi.org/10.1159/000065838
- Kuusela P, Haglund C, Roberts PJ, et al (1987). Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Br J Cancer, 55, 673-6. https://doi.org/10.1038/bjc.1987.137
- Schauer M, Peiper M, Theisen J, et al (2011). Prognostic factors in patients with diffuse type gastric cancer (linitis plastica) after operative treatment. Eur J Med Res, 16, 29-33. https://doi.org/10.1186/2047-783X-16-1-29
- Sipponen P, Kekki M, Siurala M(1988). Increased risk of gastric cancer in males affects the intestinal type of cancer and is independent of age, location of the tumour and atrophic gastritis. Br J Cancer, 57, 332-6. https://doi.org/10.1038/bjc.1988.75
- Sun Z, Wang ZN, Zhu Z, et al (2012). Evaluation of the seventh edition of American joint committee on cancer TNM staging system for gastric cancer: results from a Chinese monoinstitutional study. Ann Surg Oncol, 19, 1918-27. https://doi.org/10.1245/s10434-011-2206-1
- Zagari RM, Bazzoli F (2004). Gastric cancer: who is at risk? Dig Dis, 22, 302-5. https://doi.org/10.1159/000083590
Cited by
- CEA and CA 19-9 are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4289
- Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6295
- Clinicopathological Factors and Gastric Cancer Prognosis in the Iranian Population: a Meta-analysis vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.853
- Alpha-fetoprotein (AFP) Elevation Gastric Adenocarcinoma and Importance of AFP Change in Tumor Response Evaluation vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2003
- Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer vol.4, pp.3, 2016, https://doi.org/10.3892/mco.2015.712
- A case report of targeted therapy with apatinib in a patient with advanced gastric cancer and high serum level of alpha-fetoprotein vol.95, pp.37, 2016, https://doi.org/10.1097/MD.0000000000004610